KINE-201C

KINE-201C is an investigational peptide therapeutic being developed by Kine Science for the treatment of Chronic Obstructive Pulmonary Disease (COPD). As part of Kine Science's pipeline of 'Kine-Peptides,' KINE-201C is designed to modulate the activity of Th2 (Type 2 helper T) cells. Th2 cells are key drivers of the inflammatory and allergic responses that contribute to the pathophysiology of chronic respiratory diseases. By modulating these cells, KINE-201C aims to reduce airway inflammation and improve lung function in patients with COPD. The drug is currently in the discovery or early preclinical stage, and while its specific molecular target remains undisclosed, its mechanism focuses on restoring immune homeostasis by dampening Th2-mediated pathways.